Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England

References

• Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–458. doi:10.1016/s2213-2600(21)00511-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. The top 10 causes of death; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed September 9, 2022.
   Google Scholar
• Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ. 2022;378:e069679. doi:10.1136/bmj-2021-069679
   PubMedGoogle Scholar
• Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001–2012 and nationwide emergency department sample 2006–2011. Chest. 2015;147(4):989–998. doi:10.1378/chest.14-2146
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2022. Available from: https://goldcopd.org/archived-reports/. Accessed September 9, 2022.
   Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Çolak Y, Afzal S, Marott JL, et al. Prognosis of COPD depends on severity of exacerbation history: a population-based analysis. Respir Med. 2019;155:141–147. doi:10.1016/j.rmed.2019.07.021
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58(2):100–105. doi:10.1136/thorax.58.2.100
   PubMed Web of Science ®Google Scholar
• Johansson G, Mushnikov V, Bäckström T, et al. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm Med. 2018;18(1):17. doi:10.1186/s12890-018-0573-0
   PubMedGoogle Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018. Available from: https://www.nice.org.uk/guidance/ng115. Accessed June 16, 2022.
   Google Scholar
• Jenkins CR, Postma DS, Anzueto AR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97. doi:10.1186/s12890-015-0077-0
   PubMed Web of Science ®Google Scholar
• Jones PW, Anderson JA, Calverley PM, et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 2011;12(1):71. doi:10.1186/1465-9921-12-71
   PubMed Web of Science ®Google Scholar
• Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86. doi:10.1186/s12931-017-0566-1
   PubMedGoogle Scholar
• Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila AS. A network meta-analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) combinations in COPD. Pulm Ther. 2017;3(2):297–316. doi:10.1007/s41030-017-0048-0
   PubMedGoogle Scholar
• Ismaila AS, Haeussler K, Czira A, et al. Comparative efficacy of umeclidinium/vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: a network meta-analysis. Adv Ther. 2022. doi:10.1007/s12325-022-02234-x
   Web of Science ®Google Scholar
• Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–2533. doi:10.1007/s12325-017-0626-4
   PubMed Web of Science ®Google Scholar
• Moretz C, Bengtson LG, Sharpsten L, et al. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol. Int J Chron Obstruct Pulmon Dis. 2019;14:2047–2060. doi:10.2147/copd.S213520
   PubMed Web of Science ®Google Scholar
• Moretz C, Cole AL, Mu G, et al. Evaluation of medication adherence and rescue medication use in non-exacerbating patients with COPD receiving umeclidinium/vilanterol or budesonide/formoterol as initial maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2020;15:2207–2215. doi:10.2147/copd.s259850
   PubMed Web of Science ®Google Scholar
• Alcázar Navarrete B, Boucot I, Naya I, et al. Umeclidinium/vilanterol versus tiotropium/olodaterol in maintenance-naïve patients with moderate symptomatic chronic obstructive pulmonary disease: a post hoc analysis. Pulm Ther. 2018;4(2):171–183. doi:10.1007/s41030-018-0057-7
   PubMedGoogle Scholar
• Monteagudo M, Rodríguez-Blanco T, Llagostera M, et al. Factors associated with changes in quality of life of COPD patients: a prospective study in primary care. Respir Med. 2013;107(10):1589–1597. doi:10.1016/j.rmed.2013.05.009
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-3
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272. doi:10.1183/09031936.00051110
   PubMed Web of Science ®Google Scholar
• O’Hagan P, Chavannes NH. The impact of morning symptoms on daily activities in chronic obstructive pulmonary disease. Curr Med Res Opin. 2014;30(2):301–314. doi:10.1185/03007995.2013.857648
   PubMed Web of Science ®Google Scholar
• Czira A, Banks V, Requena G, et al. Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK. Eur Respir J. 2021;58(suppl 65):PA2411. doi:10.1183/13993003.congress-2021.PA2411
   Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740–1740g. doi:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar